8-K: Rapport Therapeutics Announces Positive Phase 1 Trial Data for RAP-219 and Chief Medical Officer Transition

Rapport Therapeutics reports positive results from its PET and MAD-2 trials for RAP-219, showing target receptor occupancy and good tolerability, while also announcing the departure of its Chief Medical Officer.

Summary

• Rapport Therapeutics announced new data from its positron emission tomography (PET) and second multiple ascending dose (MAD-2) trials for RAP-219.
• The PET trial confirmed that RAP-219 achieved target receptor occupancy (50%-70%) within five days of dosing, which is associated with maximal efficacy in preclinical models.
• The PET trial also showed that the drug's target, TARP g 8, is enriched in the hippocampus and cerebral cortex, and minimal in the cerebellum and brain stem.
• The MAD-2 trial demonstrated that RAP-219 was generally well-tolerated, with no sedation or motoric impairments observed.
• Both trials showed that target exposures and receptor occupancy were achieved within 5 days of dosing across various regimens.
• A total of 100 healthy volunteers have been exposed to RAP-219 across four Phase 1 trials, with no serious adverse events reported.
• The company also announced that Bradley Galer, M.D., has stepped down as Chief Medical Officer, and a search for his replacement is underway.
• Topline results from the ongoing Phase 2a trial in focal epilepsy are expected in mid-2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, indicating a promising drug candidate with good tolerability and efficacy. The departure of the CMO is a minor negative, but the overall tone is optimistic.

Positives

• RAP-219 achieved target receptor occupancy quickly, within five days of dosing.
• The drug demonstrated a favorable tolerability profile, with no serious adverse events reported in Phase 1 trials.
• No sedation or motoric impairments were observed, unlike many anti-seizure medications.
• The trials confirmed the neuroanatomical specificity of RAP-219, targeting the hippocampus and cerebral cortex.
• The data supports the dosing regimen selected for the ongoing Phase 2a trial in focal epilepsy.
• The company believes the pharmacokinetic and tolerability outcomes provide compelling evidence of selectively targeting TARPg8 associated AMPA receptors.

Negatives

• Bradley Galer, M.D., has stepped down as Chief Medical Officer, requiring a search for a successor.
• Three treatment discontinuations occurred (3%) that were attributed to treatment emergent adverse events.

Risks

• The company is dependent on third parties to conduct clinical trials and manufacture its product candidates.
• There are risks related to the company's financial condition and the need for substantial additional funds.
• Regulatory approvals are not guaranteed and are subject to risks.
• The company faces risks related to the competitive landscape for its product candidates.
• Interim, topline and preliminary data from clinical trials are subject to audit and verification procedures that could result in material changes in the final data.

Future Outlook

The company expects topline results from the ongoing Phase 2a trial in focal epilepsy in mid-2025 and is continuing to advance RAP-219 in clinical trials for focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania.

Management Comments

• Steve Paul, M.D., Rapport cofounder and chair of the board of directors, stated that the Phase 1 results reinforce their belief in RAP-219's distinct profile and potential to deliver transformative outcomes for patients.
• Abe Ceesay, chief executive officer of Rapport, said that RAP-219 was designed to overcome the limitations of current treatments and that the new data supports their approach as they advance the Phase 2a trial.
• The company is confident that the transition of the Chief Medical Officer will not disrupt progress across its clinical programs.

Industry Context

This announcement is significant in the context of CNS drug development, where achieving both efficacy and tolerability is a major challenge. The positive results for RAP-219, particularly its lack of sedation and motoric impairments, could position it as a differentiated treatment option compared to existing anti-seizure medications.

Comparison to Industry Standards

• Many traditional anti-seizure medications are known for causing sedation and motoric impairments, which RAP-219 appears to avoid, suggesting a potential advantage.
• The rapid achievement of target receptor occupancy within 5 days is notable, as many CNS drugs require longer periods to reach therapeutic levels.
• The selective targeting of TARPg8 is a novel approach, as many existing treatments lack this level of specificity, leading to broader side effects.
• The company's focus on precision medicine and receptor-associated proteins (RAPs) aligns with a growing trend in the pharmaceutical industry towards more targeted therapies.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients with CNS disorders may benefit from the development of RAP-219.
• Employees may be affected by the change in Chief Medical Officer, but the company is confident in a smooth transition.

Next Steps

• The company will continue the Phase 2a trial in focal epilepsy, with topline results expected in mid-2025.
• A search for a new Chief Medical Officer is underway.
• The company will continue to advance RAP-219 in clinical trials for focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania.

Key Dates

Keywords

RAP-219, TARP g 8, AMPA receptor, focal epilepsy, PET trial, MAD-2 trial, CNS disorders, neuroanatomical specificity, clinical trials, pharmacokinetics, receptor occupancy